CARDIOTOXICITY

This study tested whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, can prevent heart damage caused by anthracycline chemotherapy. 94 adults with cancer took either dapagliflozin or a placebo daily for four months alongside their chemo. Researchers meas…

This study looked at whether using a blood test (NTproBNP) to guide heart-protecting medications can safely prevent heart damage in people with breast cancer or lymphoma receiving anthracycline chemotherapy. About 108 adults participated, and researchers measured how many joined,…

This pilot study tested whether a structured exercise program is feasible for young cancer survivors (ages 18-45) who have mild heart dysfunction after cancer treatment. The program, called CORE, is like cardiac rehab and aims to improve heart health, fitness, and quality of life…

This study looked at whether a 3-month aerobic exercise program could improve heart function in 47 childhood cancer survivors who had been treated with anthracycline chemotherapy. Participants chose their own exercise and received support at a YMCA. The goal was to see if exercis…

This early-phase study tested whether the heart medication carvedilol could safely protect breast cancer patients from heart damage caused by chemotherapy drugs like doxorubicin and trastuzumab. 68 women with early-stage breast cancer were assigned to either receive carvedilol or…

This study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…

This study looked at 172 breast cancer patients to see how proton radiation compares to standard photon radiation in terms of heart health. Researchers measured heart function and blood markers before, during, and up to one year after treatment. The goal was to understand which t…

This study followed 100 people with advanced EGFR-mutant lung cancer who were taking drugs called EGFR-TKIs (erlotinib, dacomitinib, afatinib, or osimertinib). The goal was to see how often these drugs cause heart problems, specifically a drop in the heart's pumping ability. Rese…

This study looked at whether special heart MRI scans can spot early signs of heart damage in breast cancer patients after chemotherapy and radiation. Researchers followed 150 women for 12 months to see if heart swelling predicted a drop in heart function. The goal was to improve …